Injectable Drug Delivery Market By Type (Devices, Formulations), By Formulation Packaging (Ampules, Vials, Cartridges, Bottles), By Therapeutic Application (Auto-immune diseases, Hormonal Disorders, Orphan Diseases, Oncology, Other), By Usage Pattern (Curative Care, Immunization, Other), By Site of Administration (Skin, Circulatory/Musculoskeletal, Organs, Central Nervous System), By Distribution Channel (Hospitals, Retail Pharmacy Stores), By Facility of Use (Hospitals & Clinics, Home Care Settings, Other), and By Regions (North America, Europe, Middle East and Africa, Latin America and Asia Pacific) - Global Outlook to 2026
Report ID: 391268 | Feb 2020 | No. of Pages: 120
|
Covid-19 Impact Analysis & Forecast
Global Injectable Drug Delivery Market is valued USD 518.75 Million in 2019 and is projected is to exhibit 12.7% CAGR during the forecast period. The market is projected to be around USD 1197.91 Million by 2026. The market is driven by the increasing use of biologics, an increase in the prevalence of chronic diseases.
Injectable drug is directly injecting into the bloodstream through a hollow hypodermic needle and syringe, which is entered through the skin into the body. The Injectable drug delivery system is supposed to be one of the most effective routes of administration because of the speed and effectiveness of delivery to the target, and novel developments have enhanced the patient experience.
Injectable Drug Delivery Market Dynamics
The factors that drive the growth of the injectable drug delivery market are such as the increasing use of biologics, an increase in the prevalence of chronic diseases, increasing the occurrence of needlestick injuries, and the benefits of injections. Furthermore, growing disease prevalence such as diabetes, cancers, and others are reasonable to fuel the market during the forecast period.
Additionally, the market is growing due to the increasing demand for effective and convenient systems for drug delivery by patients who rely on medicines daily. This is, in turn, posing a profitable opportunity for manufacturers to develop consumer-friendly and effective injectable drug delivery services.
Injectable Drug Delivery Market Insight
Based on the region, North America is expected to dominate the market of the injectable drug delivery, due to the higher adoption of innovative injectable drug delivery technologies among patients because of their convenience, and therapeutic benefits. The factor that contributes to the growth of the market in North America is the growing prevalence of diabetes and cancer patients in the US. Additionally, the presence of major manufacturers in the region is contributing to the development of innovative injectable drug delivery devices, which is anticipated to fuel the North America market growth.
Injectable Drug Delivery Market Segmentation
The global Injectable Drug Delivery Market is segmented into type, formulation packaging, therapeutic application, usage pattern, site of administration, distribution channel, facility of use, and region. On the basis of the type the market is divided into devices, formulations. Based on formulation packaging the market is segmented into ampules, vials, cartridges, bottles. Based on therapeutic application the market is segmented into auto-immune diseases, hormonal disorders, orphan diseases, oncology, other. Based on usage pattern the market is segmented into curative care, immunization, other. Based on site of administration the market is segmented into skin, circulatory/musculoskeletal, organs, central nervous system. Based on distribution channel the market is segmented into hospitals, retail pharmacy stores. Based on facility of use the market is segmented into hospitals & clinics, home care settings, other. And based on the geography the market is further segregated into North America, Latin America, Europe and Asia Pacific.
Injectable Drug Delivery Market Competitive Landscape
The key players in Injectable Drug Delivery Market are listed as Baxter International, Nova Nordisk A/S, Becton Dickinson, Sanofi, Pfizer, InjexPharma GmbH, Terumo Corporation, Unilife Corporation, Gerresheimer AG, Vetter Pharma-Fertigung GmbH & Co. KG., Schott AG, Eli Lily & Company., Teva, Pharmaceuticals Industries Ltd., Sandoz, Ypsomed, Bespak, B. Braun Melsungen, and Other.
Injectable drug is directly injecting into the bloodstream through a hollow hypodermic needle and syringe, which is entered through the skin into the body. The Injectable drug delivery system is supposed to be one of the most effective routes of administration because of the speed and effectiveness of delivery to the target, and novel developments have enhanced the patient experience.
Injectable Drug Delivery Market Dynamics
The factors that drive the growth of the injectable drug delivery market are such as the increasing use of biologics, an increase in the prevalence of chronic diseases, increasing the occurrence of needlestick injuries, and the benefits of injections. Furthermore, growing disease prevalence such as diabetes, cancers, and others are reasonable to fuel the market during the forecast period.
Additionally, the market is growing due to the increasing demand for effective and convenient systems for drug delivery by patients who rely on medicines daily. This is, in turn, posing a profitable opportunity for manufacturers to develop consumer-friendly and effective injectable drug delivery services.
Injectable Drug Delivery Market Insight
Based on the region, North America is expected to dominate the market of the injectable drug delivery, due to the higher adoption of innovative injectable drug delivery technologies among patients because of their convenience, and therapeutic benefits. The factor that contributes to the growth of the market in North America is the growing prevalence of diabetes and cancer patients in the US. Additionally, the presence of major manufacturers in the region is contributing to the development of innovative injectable drug delivery devices, which is anticipated to fuel the North America market growth.
Injectable Drug Delivery Market Segmentation
The global Injectable Drug Delivery Market is segmented into type, formulation packaging, therapeutic application, usage pattern, site of administration, distribution channel, facility of use, and region. On the basis of the type the market is divided into devices, formulations. Based on formulation packaging the market is segmented into ampules, vials, cartridges, bottles. Based on therapeutic application the market is segmented into auto-immune diseases, hormonal disorders, orphan diseases, oncology, other. Based on usage pattern the market is segmented into curative care, immunization, other. Based on site of administration the market is segmented into skin, circulatory/musculoskeletal, organs, central nervous system. Based on distribution channel the market is segmented into hospitals, retail pharmacy stores. Based on facility of use the market is segmented into hospitals & clinics, home care settings, other. And based on the geography the market is further segregated into North America, Latin America, Europe and Asia Pacific.
Injectable Drug Delivery Market Competitive Landscape
The key players in Injectable Drug Delivery Market are listed as Baxter International, Nova Nordisk A/S, Becton Dickinson, Sanofi, Pfizer, InjexPharma GmbH, Terumo Corporation, Unilife Corporation, Gerresheimer AG, Vetter Pharma-Fertigung GmbH & Co. KG., Schott AG, Eli Lily & Company., Teva, Pharmaceuticals Industries Ltd., Sandoz, Ypsomed, Bespak, B. Braun Melsungen, and Other.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. DefinitionChapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & LimitationsChapter 3. Executive SummaryChapter 4. Market Outlook
4.1. Market Dynamics
4.1.1. Market Drivers
4.1.2. Market Restraints
4.1.3. Market Opportunities
4.2. Porter’s Analysis
4.3. Value Chain AnalysisChapter 5. Injectable Drug Delivery Market, By Type
5.1. Injectable Drug Delivery Market, By Type, 2018-2026
5.2. Devices
5.3. FormulationsChapter 6. Injectable Drug Delivery Market, By Formulation Packaging
6.1. Injectable Drug Delivery Market, by Formulation Packaging, 2018-2026
6.2. Ampules
6.3. Vials
6.4. Cartridges
6.5. BottlesChapter 7. Injectable Drug Delivery Market, By Therapeutic Application
7.1. Injectable Drug Delivery Market, by Therapeutic Application, 2018-2026
7.2. Auto-immune diseases
7.3. Hormonal Disorders
7.4. Orphan Diseases
7.5. Oncology
7.6. OtherChapter 8. Injectable Drug Delivery Market, By Usage Pattern
8.1. Injectable Drug Delivery Market, By Usage Pattern, 2018-2026
8.2. Curative Care
8.3. Immunization
8.4. OtherChapter 9. Injectable Drug Delivery Market, By Site of Administration
9.1. Injectable Drug Delivery Market, by Site of Administration, 2018-2026
9.2. Skin
9.3. Circulatory/Musculoskeletal
9.4. Organs
9.5. Central Nervous SystemChapter 10. Injectable Drug Delivery Market, By Distribution Channel
10.1. Injectable Drug Delivery Market, by Distribution Channel, 2018-2026
10.2. Hospitals
10.3. Retail Pharmacy StoresChapter 11. Injectable Drug Delivery Market, By Facility of Use
11.1. Injectable Drug Delivery Market, by Facility of Use, 2018-2026
11.2. Hospitals & Clinics
11.3. Home Care Settings
11.4. OtherChapter 12. Injectable Drug Delivery Market, By Region
12.1. Injectable Drug Delivery Market, by Region, 2018-2026
12.1.1. North America
12.1.1.1. U.S
12.1.1.2. Rest of North America
12.1.2. Europe
12.1.2.1. U.K.
12.1.2.2. Germany
12.1.2.3. France
12.1.2.4. Rest of the Europe
12.1.3. Middle East & Africa (MEA)
12.1.3.1. GCC
12.1.3.2. North Africa
12.1.3.3. South Africa
12.1.3.4. Rest of MEA
12.1.4. Latin America (LATAM)
12.1.4.1. Brazil
12.1.4.2. Rest of LATAM
12.1.5. Asia Pacific (APAC)
12.1.5.1. India
12.1.5.2. China
12.1.5.3. Japan
12.1.5.4. Rest of the APACChapter 13. Competitive Landscape
13.1.1. Key Strategies Adopted by Players
13.1.2. Market Share/Positioning AnalysisChapter 14. Company Profiles14.1. Baxter International
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives14.2. Nova Nordisk A/S
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives14.3. Becton Dickinson
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives14.4. Sanofi
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives14.5 Pfizer
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives14.6. InjexPharma GmbH
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives14.7. Terumo Corporation
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives14.8. Unilife Corporation
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives14.9. Gerresheimer AG
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives14.10. Vetter Pharma-Fertigung GmbH & Co. KG.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives14.11. Schott AG
14.11.1. Company Overview
14.11.2. Product Offerings
14.11.3. Financial Performance
14.11.4. Recent Initiatives14.12. Eli Lily & Company.
14.12.1. Company Overview
14.12.2. Product Offerings
14.12.3. Financial Performance
14.12.4. Recent Initiatives14.13. Teva Pharmaceuticals Industries Ltd.
14.13.1. Company Overview
14.13.2. Product Offerings
14.13.3. Financial Performance
14.13.4. Recent Initiatives14.14. Sandoz
14.14.1. Company Overview
14.14.2. Product Offerings
14.14.3. Financial Performance
14.14.4. Recent Initiatives14.15. Ypsomed
14.15.1. Company Overview
14.15.2. Product Offerings
14.15.3. Financial Performance
14.15.4. Recent Initiatives14.16. Bespak
14.16.1. Company Overview
14.16.2. Product Offerings
14.16.3. Financial Performance
14.16.4. Recent Initiatives14.17 B. Braun Melsungen
14.17.1. Company Overview
14.17.2. Product Offerings
14.17.3. Financial Performance
14.17.4. Recent Initiatives14.18. List of other companies
14.18.1. Company Overview
14.18.2. Product Offerings
14.18.3. Financial Performance
14.18.4. Recent InitiativesChapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
1.1. Research Objective
1.2. Scope of the Study
1.3. DefinitionChapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & LimitationsChapter 3. Executive SummaryChapter 4. Market Outlook
4.1. Market Dynamics
4.1.1. Market Drivers
4.1.2. Market Restraints
4.1.3. Market Opportunities
4.2. Porter’s Analysis
4.3. Value Chain AnalysisChapter 5. Injectable Drug Delivery Market, By Type
5.1. Injectable Drug Delivery Market, By Type, 2018-2026
5.2. Devices
5.3. FormulationsChapter 6. Injectable Drug Delivery Market, By Formulation Packaging
6.1. Injectable Drug Delivery Market, by Formulation Packaging, 2018-2026
6.2. Ampules
6.3. Vials
6.4. Cartridges
6.5. BottlesChapter 7. Injectable Drug Delivery Market, By Therapeutic Application
7.1. Injectable Drug Delivery Market, by Therapeutic Application, 2018-2026
7.2. Auto-immune diseases
7.3. Hormonal Disorders
7.4. Orphan Diseases
7.5. Oncology
7.6. OtherChapter 8. Injectable Drug Delivery Market, By Usage Pattern
8.1. Injectable Drug Delivery Market, By Usage Pattern, 2018-2026
8.2. Curative Care
8.3. Immunization
8.4. OtherChapter 9. Injectable Drug Delivery Market, By Site of Administration
9.1. Injectable Drug Delivery Market, by Site of Administration, 2018-2026
9.2. Skin
9.3. Circulatory/Musculoskeletal
9.4. Organs
9.5. Central Nervous SystemChapter 10. Injectable Drug Delivery Market, By Distribution Channel
10.1. Injectable Drug Delivery Market, by Distribution Channel, 2018-2026
10.2. Hospitals
10.3. Retail Pharmacy StoresChapter 11. Injectable Drug Delivery Market, By Facility of Use
11.1. Injectable Drug Delivery Market, by Facility of Use, 2018-2026
11.2. Hospitals & Clinics
11.3. Home Care Settings
11.4. OtherChapter 12. Injectable Drug Delivery Market, By Region
12.1. Injectable Drug Delivery Market, by Region, 2018-2026
12.1.1. North America
12.1.1.1. U.S
12.1.1.2. Rest of North America
12.1.2. Europe
12.1.2.1. U.K.
12.1.2.2. Germany
12.1.2.3. France
12.1.2.4. Rest of the Europe
12.1.3. Middle East & Africa (MEA)
12.1.3.1. GCC
12.1.3.2. North Africa
12.1.3.3. South Africa
12.1.3.4. Rest of MEA
12.1.4. Latin America (LATAM)
12.1.4.1. Brazil
12.1.4.2. Rest of LATAM
12.1.5. Asia Pacific (APAC)
12.1.5.1. India
12.1.5.2. China
12.1.5.3. Japan
12.1.5.4. Rest of the APACChapter 13. Competitive Landscape
13.1.1. Key Strategies Adopted by Players
13.1.2. Market Share/Positioning AnalysisChapter 14. Company Profiles14.1. Baxter International
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives14.2. Nova Nordisk A/S
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives14.3. Becton Dickinson
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives14.4. Sanofi
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives14.5 Pfizer
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives14.6. InjexPharma GmbH
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives14.7. Terumo Corporation
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives14.8. Unilife Corporation
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives14.9. Gerresheimer AG
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives14.10. Vetter Pharma-Fertigung GmbH & Co. KG.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives14.11. Schott AG
14.11.1. Company Overview
14.11.2. Product Offerings
14.11.3. Financial Performance
14.11.4. Recent Initiatives14.12. Eli Lily & Company.
14.12.1. Company Overview
14.12.2. Product Offerings
14.12.3. Financial Performance
14.12.4. Recent Initiatives14.13. Teva Pharmaceuticals Industries Ltd.
14.13.1. Company Overview
14.13.2. Product Offerings
14.13.3. Financial Performance
14.13.4. Recent Initiatives14.14. Sandoz
14.14.1. Company Overview
14.14.2. Product Offerings
14.14.3. Financial Performance
14.14.4. Recent Initiatives14.15. Ypsomed
14.15.1. Company Overview
14.15.2. Product Offerings
14.15.3. Financial Performance
14.15.4. Recent Initiatives14.16. Bespak
14.16.1. Company Overview
14.16.2. Product Offerings
14.16.3. Financial Performance
14.16.4. Recent Initiatives14.17 B. Braun Melsungen
14.17.1. Company Overview
14.17.2. Product Offerings
14.17.3. Financial Performance
14.17.4. Recent Initiatives14.18. List of other companies
14.18.1. Company Overview
14.18.2. Product Offerings
14.18.3. Financial Performance
14.18.4. Recent InitiativesChapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Baxter International
Nova Nordisk A/S
Becton Dickinson
Sanofi, Pfizer
InjexPharma GmbH
Terumo Corporation
Unilife Corporation
Gerresheimer AG
Vetter Pharma-Fertigung GmbH & Co. KG.
Schott AG
Eli Lily & Company.
Teva Pharmaceuticals Industries Ltd.
Sandoz
Ypsomed
Bespak
B. Braun Melsungen
Others
Nova Nordisk A/S
Becton Dickinson
Sanofi, Pfizer
InjexPharma GmbH
Terumo Corporation
Unilife Corporation
Gerresheimer AG
Vetter Pharma-Fertigung GmbH & Co. KG.
Schott AG
Eli Lily & Company.
Teva Pharmaceuticals Industries Ltd.
Sandoz
Ypsomed
Bespak
B. Braun Melsungen
Others
1. This report provides in depth analysis for changing competitive dynamics and keeps you ahead of competitors
2. Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market
3. It provides a forward looking perspective on different factors driving or restraining market growth
4. It provides an eight-year forecast assessed on the basis of how the market is expected to grow
5. It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of various market segment
6. Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Connect With Us
+1-707-633-0404
sales@search4research.com
Related reports
|
|
(COVID Version) Global Cotton Buds Market Status (2016-2020) and Forecast (2021E-2026F) by Region, Product Type & End-Use
Publication Month: Oct 2022 | No. of Pages: 105
|
$3000Buy Now |
|
|
(COVID Version) Global Cotton Balls and Swabs Market Status (2016-2020) and Forecast (2021E-2026F) by Region, Product Type & End-Use
Publication Month: Oct 2022 | No. of Pages: 110
|
$3000Buy Now |
|
|
(COVID Version) Global Cosmetic Surgery Equipment Market Status (2016-2020) and Forecast (2021E-2026F) by Region, Product Type & End-Use
Publication Month: Oct 2022 | No. of Pages: 108
|
$3000Buy Now |
|
|
(COVID Version) Global Cosmetic Prostheses Market Status (2016-2020) and Forecast (2021E-2026F) by Region, Product Type & End-Use
Publication Month: Oct 2022 | No. of Pages: 100
|
$3000Buy Now |
|
|
(COVID Version) Global Cortisone Market Status (2016-2020) and Forecast (2021E-2026F) by Region, Product Type & End-Use
Publication Month: Oct 2022 | No. of Pages: 103
|
$3000Buy Now |